{
    "clinical_study": {
        "@rank": "77482", 
        "brief_summary": {
            "textblock": "The purpose of this study is to:\n\n      1) Determine the effects of fluoxetine in the treatment of depersonalization disorder, 2)\n      Assess the durability of treatment response in these patients, 3) Assess the improvement in\n      psychiatric disability in these patients, and 4) Assess the effects of comorbid Axis I\n      disorders (depression, social phobia, panic/anxiety, obsessive-compulsive disorder) and Axis\n      II personality disorders on treatment outcome in these patients."
        }, 
        "brief_title": "Study of Fluoxetine in Patients With Depersonalization Disorder", 
        "condition": "Depersonalization Disorder", 
        "condition_browse": {
            "mesh_term": "Depersonalization"
        }, 
        "detailed_description": {
            "textblock": "In this trial, participants will be randomly assigned to receive either fluoxetine or\n      placebo. Treatment will consists of two phases (acute treatment and maintenance). In the\n      acute treatment phase, participants will receive fluoxetine or placebo daily for 12 weeks.\n      Participants will be followed every 2 weeks. In the Maintenance phase, participants showing\n      significant improvement after 12 weeks may continue treatment for an additional 6 months. In\n      this phase, participants are followed every 4 weeks.\n\n      Participants who do not improve during the acute treatment phase may receive open\n      fluoxetine, or another appropriate medication, for 3 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusioin Criteria:\n\n          -  Meets DSM-IV criteria for depersonalization disorder in the last month\n\n        Exclusion Criteria:\n\n          -  Prior or concurrent bio- or chemotherapy or\n\n          -  Use of any of the following within 2 weeks prior to study entry: antipsychotics,\n             anticonvulsants, stimulants, barbiturates, lithium, benzodiazepines, or\n             antidepressants\n\n          -  Use of MAO inhibitors or investigational drugs within 4 weeks prior to study entry\n\n          -  History of fluoxetine use at a dose of 10 mg or more for at least 6 weeks duration\n\n          -  Hematologic, hepatic, renal, cardiovascular, pulmonary, metabolic, endocrine,\n             systemic, or gastrointestinal disease\n\n          -  History of mental disorders\n\n          -  Current substance abuse\n\n          -  Current eating disorder\n\n          -  Current clinically unstable suicidal ideation\n\n          -  Unstable medical illness\n\n          -  Clinically unstable\n\n          -  Clinically important abnormalities in lab tests or physical exams\n\n          -  History of seizure disorders or abnormal electroencephalogram\n\n          -  Hypersensitivity or severe side effects to fluoxetine\n\n          -  Pregnancy or breast-feeding. Women of child-bearing potential must use effective\n             contraception"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "65 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "80", 
        "firstreceived_date": "October 18, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004446", 
            "org_study_id": "199/13456", 
            "secondary_id": "MTS-GCO-95-323"
        }, 
        "intervention": {
            "intervention_name": "fluoxetine", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Fluoxetine"
        }, 
        "keyword": [
            "depersonalization disorder", 
            "neurologic and psychiatric disorders", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10029"
                }, 
                "name": "Mount Sinai Medical Center, NY"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "overall_official": {
            "affiliation": "Mount Sinai School of Medicine", 
            "last_name": "Daphne Simeon", 
            "role": "Study Chair"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "reference": {
            "PMID": "15231553", 
            "citation": "Simeon D, Guralnik O, Schmeidler J, Knutelska M. Fluoxetine therapy in depersonalisation disorder: randomised controlled trial. Br J Psychiatry. 2004 Jul;185:31-6."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004446"
        }, 
        "source": "National Institute of Mental Health (NIMH)", 
        "sponsors": {
            "collaborator": {
                "agency": "Mount Sinai School of Medicine", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "National Institute of Mental Health (NIMH)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "April 1998", 
        "study_design": "Allocation: Randomized, Masking: Double-Blind, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2005"
    }, 
    "geocoordinates": {
        "Mount Sinai Medical Center, NY": "40.714 -74.006"
    }
}